Boston Scientific Corporation (BSX): Stephen Mandel Opens New Position in Medical Device Firm

We just covered Lone Pine’s Non-AI Strategy Falters: 10 Non-AI Stocks Weighing Down Stephen Mandel’s 2026 Returns and Boston Scientific Corporation (NYSE:BSX) ranks 1st on this list.

Boston Scientific Corporation (NYSE:BSX) is a new addition to the 13F portfolio of Lone Pine Capital. Filings for the fourth quarter of 2025 show that the fund owned a little over 200,000 shares in the company. Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, and single-use scopes used for diagnostic and therapeutic procedures.

7 Hot Growth Stocks to Invest in Right Now

Boston Scientific Corporation (NYSE:BSX) beat Q1 estimates with $5.20 billion in revenue and $0.80 EPS, but the stock price experienced volatility because management lowered full-year 2026 guidance. Many hedge funds view this guidance cut, now projecting 6.5%–8% organic growth, as a strategic reset. By lowering the bar, management has cleared the way for future beat and raise quarters. Funds are particularly bullish on the Cardiovascular segment, which grew 11.2% organically in Q1. The Pulsed Field Ablation (PFA) platform of the firm remains a major structural moat. Recent clinical trials showed superior long-term success for atrial fibrillation treatment compared to traditional methods. Institutional investors are rewarding the 19% global growth of the WATCHMAN device as well. New data from the CHAMPION-AF study positioned it as a first-line option for stroke risk reduction.

READ NEXT15 Safe Stocks to Invest In For Beginners and 10 Best Stocks to Buy According to Nancy Pelosi.

Disclosure: None. Follow Insider Monkey on Google News.